Marginal Zone Lymphoma
J&J’s Imbruvica scores fifth FDA lymphoma approval
January 20, 2017Medical Communications, Research and Development, Sales and Marketing FDA, Marginal Zone Lymphoma, imbruvica
Johnson & Johnson’s Imbruvica (ibrutinib) has scored its fifth indication approval in the US for the treatment of Marginal Zone …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
